Business

mass. movers

Aegerion climbs a second straight day

Aegerion’s Juxtapid drug is used to treat cholesterol disease.
istockphoto.com
Aegerion’s Juxtapid drug is used to treat cholesterol disease.
Advertisement

Aegerion Pharmaceuticals Inc. rose on Tuesday and Wednesday even after it posted a wider net quarterly loss of $18.9 million amid higher expenses. Aegerion raised its revenue expectations for the year to reflect recent results from the launch of its genetic cholesterol-disease drug, Juxtapid, its sole product on the market. Aegerion raised its net revenue expectation to $30 million to $35 million, from earlier guidance of $15 million to $25 million.